Lixisenatide

Basic Description

​ Structure and function:
Lixisenatide is a synthetic peptide drug that is a glucagon-like peptide-1 (GLP-1) receptor agonist.
It is composed of 44 amino acids and can mimic the effects of GLP-1 in the human body.
By activating the GLP-1 receptor, lixisenatide can promote the secretion of insulin and inhibit the release of glucagon, thereby lowering blood sugar levels.
Lixisenatide also has the effect of delaying gastric emptying and reducing appetite, which helps to control weight.
In vitro and in vivo studies:
In in vitro experiments, lixisenatide can significantly increase insulin secretion from pancreatic β cells and inhibit glucagon secretion from α cells.
In vivo experiments, lixisenatide can effectively reduce postprandial blood glucose levels and improve glycated hemoglobin (HbA1c) levels in patients with type 2 diabetes.
Clinical trials have shown that lixisenatide can reduce the risk of cardiovascular events while lowering blood sugar.

​ ​Three-letter sequence​

​ ​Single letter sequence​

CAS Number

Molecular formula

Molecular weight

purity

>98%

form

Lyophilized powder

Storage conditions

Store at -20°C/-80°C away from light